N/A
Completed N=480
Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control
Source: ClinicalTrials.gov NCT01651117 ↗Enrolled (actual)
480
Serious AEs
10.8%
Results posted
Sep 2019
Primary outcomePrimary: Change in Glucose Control (Stage 1: Usual Care v. Peer Mentoring) — -0.1978; -0.5246 percent — p=0.0611
Summary
The purpose of this study is to test the effectiveness of a peer mentor model in a mixed race population of poorly controlled diabetic Veterans. Also, the study aims to assess the effects of becoming a mentor on those who originally were mentees. It is expected that participants in the peer mentoring arms (Arm 2 and 3) will have improved glucose control regardless of race or ethnicity at the end of the intervention.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Glucose Control (Stage 1: Usual Care v. Peer Mentoring) |
-0.1978; -0.5246 | 0.0611 |
| PRIMARY Change in Glucose Control (Stage 2: Usual Care v. Mentees) |
-0.2661; -0.1628 | — |
| PRIMARY Change in Glucose Control (Stage 2: Non-mentors v. Mentors) |
0.2396; 0.0639 | — |
| SECONDARY Change in Direct LDL Blood Levels |
-7.1706; -7.8594 | — |
| SECONDARY Change in Systolic Blood Pressure |
-3.7548; -2.3274 | — |
| SECONDARY Change in Diabetes Quality of Life Score |
0.0159; -0.0371 | — |
| SECONDARY Change in Depression Symptoms |
-0.1168; -0.1736 | — |
| SECONDARY Change in Glucose Control |
-0.2643; -0.2818 | — |
| SECONDARY Change in Diabetes Quality of Life |
-0.1213; -0.1812 | — |
| SECONDARY Change in Direct LDL Blood Levels (Stage 2: Usual Care v. Mentees) |
5.0419; -4.9126 | — |
| SECONDARY Change in Systolic Blood Pressure (Stage 2: Usual Care v. Mentee) |
-1.6851; 1.3877 | — |
| SECONDARY Change in Diabetes Quality of Life (Stage 2: Usual Care v. Mentee) |
-0.1299; -0.0246 | — |
| SECONDARY Change in Depression Symptoms (Stage 2: Usual Care v. Mentees) |
-0.4581; -0.0890 | — |
| SECONDARY Change in Glucose Control (Stage 2: Usual Care v. Mentees) |
-0.2661; -0.1628 | — |
| SECONDARY Change in Direct LDL Blood Levels (Stage 2: Non-mentors v. Mentors) |
-1.0938; 2.2494 | — |
| SECONDARY Change in Systolic Blood Pressure (Stage 2: Non-mentors v. Mentors) |
-3.9453; -0.5611 | — |
| SECONDARY Change in Diabetes Quality of Life (Stage 2: Non-mentors v. Mentors) |
-0.1896; -0.3017 | — |
| SECONDARY Change in Depression Symptoms (Stage 2: Non-mentors v. Mentors) |
0.0609; -0.0819 | — |
| SECONDARY Change in Glucose Control (Stage 2: Non-mentors v. Mentors) |
0.2396; 0.0639 | — |
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria
- All participants must have a diagnosis of Type 2 diabetics.
- Diabetes began after age 30
- Mentees: Have an HbA1c > 8% on 2 different occasions in the course of 24 months, with at least one measure within 3 months of enrollment
- Mentors for Phase 1: Had an HbA1c of > 8% in the past 3 years and an HbA1c < (or equal to) 7.5% within 3 months of enrollment
- Mentors for Phase 2: Former mentee
Exclusion Criteria
Exclusion Criteria
- Does not speak English
- Unable to understand consents
- Severe speech impediment
- over the age of 75
Data sourced from ClinicalTrials.gov (NCT01651117). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.